HARVARD BIOSCIENCE INC (HBIO) Stock Fundamental Analysis
USA - NASDAQ:HBIO - US4169061052 - Common Stock
0.4079 USD
+0 (+1.02%)
We assign a fundamental rating of 3 out of 10 to HBIO. HBIO was compared to 57 industry peers in the Life Sciences Tools & Services industry. HBIO may be in some trouble as it scores bad on both profitability and health. HBIO has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
In the past year HBIO was profitable.
HBIO had a positive operating cash flow in the past year.
HBIO had negative earnings in each of the past 5 years.
In the past 5 years HBIO always reported a positive cash flow from operatings.
1.2 Ratios
HBIO has a Return On Assets of -71.67%. This is amonst the worse of the industry: HBIO underperforms 89.47% of its industry peers.
With a Return On Equity value of -364.88%, HBIO is not doing good in the industry: 87.72% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| ROIC | N/A |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of HBIO (56.89%) is better than 73.68% of its industry peers.
In the last couple of years the Gross Margin of HBIO has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for HBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
2. Health
2.1 Basic Checks
HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HBIO has been increased compared to 1 year ago.
The number of shares outstanding for HBIO has been increased compared to 5 years ago.
Compared to 1 year ago, HBIO has a worse debt to assets ratio.
2.2 Solvency
HBIO has an Altman-Z score of -2.72. This is a bad value and indicates that HBIO is not financially healthy and even has some risk of bankruptcy.
HBIO has a worse Altman-Z score (-2.72) than 82.46% of its industry peers.
There is no outstanding debt for HBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 8.44 | ||
| Altman-Z | -2.72 |
ROIC/WACCN/A
WACC9.82%
2.3 Liquidity
HBIO has a Current Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.81, HBIO is not doing good in the industry: 92.98% of the companies in the same industry are doing better.
A Quick Ratio of 0.41 indicates that HBIO may have some problems paying its short term obligations.
HBIO has a worse Quick ratio (0.41) than 96.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
HBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -71.43%.
The earnings per share for HBIO have been decreasing by -19.73% on average. This is quite bad
Looking at the last year, HBIO shows a very negative growth in Revenue. The Revenue has decreased by -12.24% in the last year.
The Revenue has been decreasing by -4.12% on average over the past years.
EPS 1Y (TTM)-71.43%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%23.48%
Revenue 1Y (TTM)-12.24%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-11.46%
3.2 Future
HBIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.08% yearly.
Based on estimates for the next years, HBIO will show a decrease in Revenue. The Revenue will decrease by -1.21% on average per year.
EPS Next Y-57.5%
EPS Next 2Y27.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 20.39 indicates a rather expensive valuation of HBIO.
Based on the Price/Earnings ratio, HBIO is valued cheaply inside the industry as 84.21% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of HBIO to the average of the S&P500 Index (26.91), we can say HBIO is valued slightly cheaper.
A Price/Forward Earnings ratio of 4.21 indicates a rather cheap valuation of HBIO.
HBIO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HBIO is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.92. HBIO is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.4 | ||
| Fwd PE | 4.21 |
4.2 Price Multiples
HBIO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HBIO is cheaper than 85.96% of the companies in the same industry.
HBIO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HBIO is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.4 | ||
| EV/EBITDA | 15.31 |
4.3 Compensation for Growth
HBIO's earnings are expected to grow with 27.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.08%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for HBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HBIO (10/24/2025, 7:32:10 PM)
0.4079
+0 (+1.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners58.21%
Inst Owner Change0.51%
Ins Owners3.72%
Ins Owner Change11.11%
Market Cap18.16M
Revenue(TTM)88.75M
Net Income(TTM)-57406000
Analysts80
Price Target2.04 (400.12%)
Short Float %1.64%
Short Ratio0.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.73%
Min EPS beat(2)1.96%
Max EPS beat(2)75.49%
EPS beat(4)3
Avg EPS beat(4)-19.61%
Min EPS beat(4)-173.52%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-36.43%
EPS beat(12)5
Avg EPS beat(12)-34.08%
EPS beat(16)5
Avg EPS beat(16)-29.83%
Revenue beat(2)1
Avg Revenue beat(2)4.73%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)11.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.43%
Min Revenue beat(4)-14.86%
Max Revenue beat(4)11.18%
Revenue beat(8)1
Avg Revenue beat(8)-5.4%
Revenue beat(12)2
Avg Revenue beat(12)-5.25%
Revenue beat(16)3
Avg Revenue beat(16)-4.28%
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)0%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.4 | ||
| Fwd PE | 4.21 | ||
| P/S | 0.2 | ||
| P/FCF | 4.4 | ||
| P/OCF | 2.74 | ||
| P/B | 1.15 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.31 |
EPS(TTM)0.02
EY4.9%
EPS(NY)0.1
Fwd EY23.76%
FCF(TTM)0.09
FCFY22.74%
OCF(TTM)0.15
OCFY36.47%
SpS1.99
BVpS0.35
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.4
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.89% | ||
| FCFM | 4.65% |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 8.44 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 36.42% | ||
| Cap/Sales | 2.81% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 223.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -2.72 |
F-Score4
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.43%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%23.48%
EPS Next Y-57.5%
EPS Next 2Y27.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.24%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-11.46%
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4466.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.77%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%
HARVARD BIOSCIENCE INC / HBIO FAQ
What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to HBIO.
What is the valuation status of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a valuation rating of 7 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Undervalued.
Can you provide the profitability details for HARVARD BIOSCIENCE INC?
HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.
What is the expected EPS growth for HARVARD BIOSCIENCE INC (HBIO) stock?
The Earnings per Share (EPS) of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -57.5% in the next year.